• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同步性多原发性肺癌的早期临床诊断

Early clinical diagnosis of synchronous multiple primary lung cancer.

作者信息

Xue Xinying, Xue Qingliang, Wang Na, Zhang Lina, Guo Lina, Li Xinfu, Sun Junping, Wang Jianxin

机构信息

The Respiratory Diseases Department of the Chinese PLA General Hospital, Beijing 100853, P.R. China.

出版信息

Oncol Lett. 2012 Jan;3(1):234-237. doi: 10.3892/ol.2011.452. Epub 2011 Oct 19.

DOI:10.3892/ol.2011.452
PMID:22740887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3362344/
Abstract

The diagnosis of synchronous multiple primary lung cancer (SMPLC) remains a formidable challenge. The aim of the present study was to identify useful clues for the clinical diagnosis of SMPLC, in particular for the early stages. The medical records of 10 patients diagnosed with SMPLC with different histological types were analyzed retrospectively. Chest computed tomography (CT) findings showed two pulmonary lesions in all patients. The two lesions displayed malignant characteristics of primary lung cancer. The levels of a number of tumor markers, including carcinoembryonic antigen, neuron-specific enolase, cytokeratin fragment 21-1, squamous cell carcinoma and CA125 increased in 2 patients. Auxiliary examinations of other physical sites in these patients did not show signs of neoplasm metastasis. Two tumors were separately staged and appropriate treatment was carried out based on the revised stage, which provided more benefits for SMPLC patients. The diagnosis of SMPLC might be delayed or mistaken owing to its similarity to neoplasm metastasis. A high index of awareness is required for the early diagnosis of this disease. The malignant characteristics of primary lung cancer in various lesions may be valuable clues for the diagnosis of SMPLC. Alterations in the levels of tumor markers may be a poor diagnostic tool for the detection of SMPLC. Separate biopsies for different pulmonary masses should be performed for clinical staging as soon as possible and reasonable treatment based on the stage should also be selected.

摘要

同步性多原发性肺癌(SMPLC)的诊断仍然是一项艰巨的挑战。本研究的目的是为SMPLC的临床诊断,尤其是早期诊断寻找有用线索。回顾性分析了10例诊断为不同组织学类型SMPLC患者的病历。胸部计算机断层扫描(CT)结果显示所有患者均有两个肺部病灶。这两个病灶表现出原发性肺癌的恶性特征。2例患者中,包括癌胚抗原、神经元特异性烯醇化酶、细胞角蛋白片段21-1、鳞状细胞癌和CA125在内的多种肿瘤标志物水平升高。这些患者其他身体部位的辅助检查未显示肿瘤转移迹象。对两个肿瘤分别进行分期,并根据修订后的分期进行适当治疗,这为SMPLC患者带来了更多益处。由于SMPLC与肿瘤转移相似,其诊断可能会延迟或有误。早期诊断这种疾病需要高度的警惕性。各个病灶中原发性肺癌的恶性特征可能是SMPLC诊断的有价值线索。肿瘤标志物水平的改变可能不是检测SMPLC的良好诊断工具。应尽快对不同肺部肿块进行单独活检以进行临床分期,并根据分期选择合理的治疗方法。

相似文献

1
Early clinical diagnosis of synchronous multiple primary lung cancer.同步性多原发性肺癌的早期临床诊断
Oncol Lett. 2012 Jan;3(1):234-237. doi: 10.3892/ol.2011.452. Epub 2011 Oct 19.
2
Radiological classification, gene-mutation status, and surgical prognosis of synchronous multiple primary lung cancer.同步多原发肺癌的放射学分类、基因突变状态和外科预后。
Eur Radiol. 2022 Jun;32(6):4264-4274. doi: 10.1007/s00330-021-08464-x. Epub 2022 Jan 6.
3
Clinical and pathologic staging accuracy in patients with synchronous multiple primary lung cancers.同步性多原发性肺癌患者的临床及病理分期准确性
J Thorac Dis. 2024 Jan 30;16(1):491-497. doi: 10.21037/jtd-23-1383. Epub 2024 Jan 29.
4
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.细胞角蛋白19片段CYFRA 21-1与癌胚抗原、鳞状细胞癌抗原及神经元特异性烯醇化酶在肺癌中的比较:一项国际多中心研究结果
Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):189-99.
5
Contemporary Incidence of Synchronous Multiple Primary Lung Cancers and Survival in the Era of Lung Cancer Screening.当代肺癌筛查时代同步多原发肺癌的发病率和生存情况。
Innovations (Phila). 2024 Jan-Feb;19(1):23-29. doi: 10.1177/15569845231210242. Epub 2023 Nov 29.
6
Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers?同步多原发性肺癌的手术治疗结果:与分期匹配的单发性原发性肺癌相似?
Ann Thorac Surg. 2013 Dec;96(6):1966-74. doi: 10.1016/j.athoracsur.2013.04.142. Epub 2013 Sep 7.
7
Real-world comprehensive diagnosis and "Surgery + X" treatment strategy of early-stage synchronous multiple primary lung cancer.早期同步性多原发性肺癌的真实世界综合诊断与“Surgery+X”治疗策略。
Cancer Med. 2023 Jun;12(12):12996-13006. doi: 10.1002/cam4.5972. Epub 2023 Apr 20.
8
Surgical treatment of synchronous multiple primary lung cancers: a retrospective analysis of 122 patients.同期多发原发性肺癌的外科治疗:122例患者的回顾性分析
J Thorac Dis. 2016 Jun;8(6):1197-204. doi: 10.21037/jtd.2016.04.46.
9
[Analysis on the Prognostic and Survival Factors of Synchronous Multiple Primary Lung Cancer].[同步性多原发性肺癌的预后及生存因素分析]
Zhongguo Fei Ai Za Zhi. 2017 Jan 20;20(1):21-27. doi: 10.3779/j.issn.1009-3419.2017.01.03.
10
[Synchronous Multiple Primary Lung Cancer Dignosed 
by Different Phenotype-genotype: A Case Report and Literature Review].[通过不同表型-基因型诊断的同步多原发性肺癌:病例报告及文献综述]
Zhongguo Fei Ai Za Zhi. 2017 Dec 20;20(12):857-860. doi: 10.3779/j.issn.1009-3419.2017.12.11.

引用本文的文献

1
Distinguishing MPLCs from IPMs using NGS-based molecular algorithms and histological assessment: A systematic review and validation study.使用基于二代测序的分子算法和组织学评估区分多原发性肺癌与肺内转移癌:一项系统评价与验证研究
Medicine (Baltimore). 2025 Feb 21;104(8):e41673. doi: 10.1097/MD.0000000000041673.
2
[Synchronous association of two primary lung tumors: a case report].[两例原发性肺肿瘤的同步关联:病例报告]
Pan Afr Med J. 2023 Aug 21;45:174. doi: 10.11604/pamj.2023.45.174.31477. eCollection 2023.
3
Sublobar resection versus lobectomy in the treatment of synchronous multiple primary lung cancer.亚肺叶切除术与肺叶切除术治疗同期多原发性肺癌的比较。
World J Surg Oncol. 2023 Apr 24;21(1):135. doi: 10.1186/s12957-023-02996-w.
4
Development and Validation of a Nomogram for Predicting Overall Survival in Patients with Second Primary Small Cell Lung Cancer After Non-Small Cell Lung Cancer: A SEER-Based Study.非小细胞肺癌后发生第二原发性小细胞肺癌患者总生存预测列线图的开发与验证:一项基于监测、流行病学和最终结果(SEER)数据库的研究
Int J Gen Med. 2022 Apr 2;15:3613-3624. doi: 10.2147/IJGM.S353045. eCollection 2022.
5
Surgical treatment for synchronous multiple primary lung cancer: Is it possible to achieve both curability and preservation of the pulmonary function?同步多原发性肺癌的外科治疗:是否可以同时达到治愈性和肺功能的保留?
Thorac Cancer. 2021 Nov;12(22):2996-3004. doi: 10.1111/1759-7714.14164. Epub 2021 Sep 30.
6
A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib.一例携带表皮生长因子受体突变和间变性淋巴瘤激酶重排的同步性多原发性肺腺癌患者经奥希替尼和阿来替尼联合治疗成功治愈。
Respir Med Case Rep. 2021 Apr 13;33:101418. doi: 10.1016/j.rmcr.2021.101418. eCollection 2021.
7
A rare case of synchronous multiple primary lung cancer with different responses to gefitinib.一例罕见的同步性多原发性肺癌对吉非替尼有不同反应的病例。
Respir Med Case Rep. 2020 Oct 24;31:101270. doi: 10.1016/j.rmcr.2020.101270. eCollection 2020.
8
CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas.多原发肺腺癌患者中与 EGFR 突变和 ALK 阳性相关的 CT 特征。
Cancer Imaging. 2020 Jul 20;20(1):51. doi: 10.1186/s40644-020-00330-1.
9
Clinical treatment of advanced synchronous triple primary malignancies: comprehensive treatment based on targeted therapy.晚期同步性三原发性恶性肿瘤的临床治疗:基于靶向治疗的综合治疗
Onco Targets Ther. 2019 Apr 2;12:2421-2430. doi: 10.2147/OTT.S200625. eCollection 2019.
10
Multiple primary lung cancer: a rising challenge.多发性原发性肺癌:一项日益严峻的挑战。
J Thorac Dis. 2019 Mar;11(Suppl 4):S523-S536. doi: 10.21037/jtd.2019.01.56.

本文引用的文献

1
[Therapeutic strategy for secondary lung cancer].
Kyobu Geka. 2010 Oct;63(11):956-61.
2
Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.包括前胃泌素释放肽在内的血清肿瘤标志物在肺癌患者中的应用价值:与组织学的相关性
Tumour Biol. 2009;30(3):121-9. doi: 10.1159/000224628. Epub 2009 Jun 9.
3
Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients.同步性多原发性肺癌的外科治疗:92例患者的经验
J Thorac Cardiovasc Surg. 2007 Sep;134(3):630-7. doi: 10.1016/j.jtcvs.2007.06.001.
4
The results of therapy for bilateral multiple primary lung cancers: 30 years experience in a single centre.双侧多发性原发性肺癌的治疗结果:单中心30年经验
Eur J Surg Oncol. 2004 Sep;30(7):781-5. doi: 10.1016/j.ejso.2004.05.008.
5
ProGRP: a new biomarker for small cell lung cancer.胃泌素释放肽前体:一种用于小细胞肺癌的新型生物标志物。
Clin Biochem. 2004 Jul;37(7):505-11. doi: 10.1016/j.clinbiochem.2004.05.007.
6
Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).胃泌素释放肽前体(ProGRP)和神经元特异性烯醇化酶(NSE)在小细胞肺癌(SCLC)诊断和预后中的互补作用。
Lung Cancer. 2001 Apr;32(1):61-9. doi: 10.1016/s0169-5002(00)00205-1.
7
Survival in synchronous vs. single lung cancer: upstaging better reflects prognosis.同步性肺癌与单发肺癌的生存率:分期上调更能反映预后。
Chest. 2000 Oct;118(4):952-8. doi: 10.1378/chest.118.4.952.
8
Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.胃泌素释放肽前体、神经元特异性烯醇化酶和嗜铬粒蛋白A作为小细胞肺癌的血清标志物。
Lung Cancer. 2000 Sep;29(3):197-203. doi: 10.1016/s0169-5002(00)00113-6.
9
Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.血清胃泌素释放肽前体作为小细胞肺癌复发预测指标的意义:与神经元特异性烯醇化酶和癌胚抗原的比较评估
Lung Cancer. 2000 Mar;27(3):159-67. doi: 10.1016/s0169-5002(99)00100-2.
10
Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA.对2361例接受I期、II期和IIIA期非小细胞肺癌肺切除术患者的预后评估。
Chest. 2000 Feb;117(2):374-9. doi: 10.1378/chest.117.2.374.